Supplemental Table 2 – Patient Characteristics and Summary of Interventions/Outcomes.

Study	Sample Size	Participant Type	1. ISS* 2. Age* 3. Male (%)	Intervention	Outcomes / Main Findings
Massive Hem	orrhage Co	ntrol			
Smith 2019 [18]	238	Patients with extremity injuries	1. 10.9 ^a 2. 34.5 ^a 3. 87%	 Tourniquet No tourniquet 	Tourniquet: 1. Associated with ↑ SBP on arrival 2. ↓blood products use 3. ↓ limb related complications
Winstanley 2019 [23]	3792	Injured patients NISS ≥15, with extremity injuries	1. 36.0 ^a 2. 24.8 ^b 3. 97.2%	 Hemostatic agent No hemostatic agent 	Hemostatic agents: 1. Associated with improved survival in those more severely injured
Duignan 2018 [33]	84	Serious bleeding from extremity injury	1. NR 2. NR 3. 73.8%	 Tourniquet No tourniquet 	Tourniquet: 1. All tourniquet applications were inappropriate 2. No complications resulted
Kauvar 2018 [25]	455	≥1 arterial injury to main lower limb	1. NR 2. NR 3. NR	 Tourniquet No tourniquet 	 Field tourniquet: 1. ↑ wound infection 2. ↑ Neuro compromise but not limb loss
Schauer 2018 [29]	28212	Traumatically injured patients	1. NR 2. NR 3. NR	 Hemostatic No Hemostatic 	Hemostatic agents: 1. ↑ use in GSW, traumatic amputations, tourniquet application 2. ↑ blood product use
Schauer 2017 [31]	705	Casualties in Afghanistan	1. NR 2. NR 3. NR	1. QCCG 2. Non-QCCG	QCCG casualties: 1. Had ↑ GSWs vs. baseline population 2. Hemorrhage control success similar to other military and civilian reports
Dunn 2016 [20]	24	Trauma with extremity injuries	1. NR 2. 25.0 ^a 3. NR	 Tourniquet No comparison 	Tourniquet: 1. High survivability of patients transported with tourniquet 2. Authors support battlefield tourniquet application
Kragh 2015 [28]	1413	Military casualties in Afghanistan or Iraq	1. 20.0 ^a 2. 24.0 ^b 3. NR	 Tourniquet No tourniquet 	Tourniquet: 1. Associated with worse shock and ↑ transfusion requirements 2. Survival rates similar to transfused casualties with no tourniquets
Ode 2015 [27]	56	Patients with penetrating limb injuries or open bleeding fractures	1. 9.0 ^b 2. NR 3. NR	 Tourniquet No tourniquet 	Tourniquet: 1. Majority of tourniquets applied appropriately to civilians requiring hemorrhage control
Bonner 2011 [61]	167	Military trauma in Afghanistan who had a pelvic x-ray	1. NR 2. NR 3. NR	 Pelvic binder application No comparator 	Pelvic binder:1. Application above level of greatertrochanters is common and does not reducepelvic fractures2. Likely to delay cardiovascular recovery
Pozza 2011 [30]	21	Soldiers with GSWs treated with local hemostatic care	1. NR 2. NR 3. 100%	1. Celox 2. No Celox	Celox granules: 1. Quick and efficient haemostatic action producing a stable clot
Pollak 2010 [32]	218	Injured combat patients	1. NR 2. NR 3. NR	 NPWT during aeromedical evacuation No comparator 	Negative pressure wound therapy: 1. Seems safe and feasible 2. Complications due to injury severity, unrelated to NPWT failure.
Clasper 2009 [24]	44	Military combat casualties	1. NR 2. NR 3. NR	 Tourniquet No tourniquet 	Tourniquet: 1. Significant ↑ in deep infection rate (32% vs. 4.5%)

1

Cox	44	Patients with	1. NR	1. QuikClot	Hemostatic agents:
2009 [17]		IED injuries or	2. NR	2. HemCon	1. Stop or ↓ bleeding
		GSWs	3. NR	3. QuikClot +	2. HemCon appears safe, QuikClot may
				HemCon	produce superficial burns
Beekley	165	Patients with	1. NR	1. Tourniquet	Tourniquet:
2008 [19]		amputations	2. NR	2. No tourniquet	1. ↑ Prehospital hemorrhage control, notably
		and vascular	3. NR		in those ISS>15
		injuries			2. 57% of deaths preventable with early use
					3. No early adverse outcomes
Brodie	70	Casualties treated	1. 16.0 ^b	1. Tourniquet	Tourniquet:
2007 [22]		at field hospitals	2. NR	2. No comparator	1. Prehospital use can be life saving for
		in Iraq and	3. NR		severe isolated limb injuries, profound
		Afghanistan			hypovolemic shock and need for massive transfusion
Lakstein	91	Soldiers, civilians	1. NR	1. Tourniquet applied	Tourniquet:
2002 [21]	91	and casualties of	2. NR	in prehospital setting	1. Effective and easy method for preventing
2002 [21]		combat or	2. NR 3. NR	2. No comparator	exsanguination in military prehospital
		terrorist attacks	5. IW	2. 110 comparator	setting
Airway Mana	gement	terrorist attacks	1		setting
Schauer	216	Trauma patients	1. NR	1. SGA en-route to	All interventions:
2019 [34]		treated in the	2. NR	military ED	1. No difference in short-term outcomes
· · · [• ·]		prehospital	3. 98.14%	2. CTY en-route to	comparing both interventions
		setting		military ED	r G G G G G G G G G G G G G G G G G G G
Hardy	617	Combat trauma	1. 14.0 ^a (14)	1. BVM	All interventions:
2018 [37]		treated in the	2. 25.0 ^a (5)	2. SGA	1. SGA ↑ morbidity
		prehospital setting	3.98%	3. CTY	2. No difference in survival between groups
Shavit	65	Patients	1.NR	1. ETI	All interventions:
2018 [38]		treated in the	2. 22.0 ^b (17-	2. LMA	1. In failed ETI, LMA can effectively treat
		prehospital	30)		combat casualties during a short transport
		setting	3.100%		time
Barnard	34	Patients	1. NR	1. CTY	Cricothyrotomy:
2014 [40]		with combat	2. NR	2. No comparator	1. Procedural success was higher than
- 1		trauma	3.97.0%		previously reported
Lockey	7256	Patients treated	1. NR	1. Intubation by non-	Intubation:
2014 [35]		in the	2. NR	anesthetists	1. Non-anesthetists 2x more likely to
		prehospital	3. NR	2. Intubation by	perform rescue airway intervention vs anesthetists
Struck	23	setting Patients treated in	1. NR	anesthetists 1. Tracheal intubation	Intubation adjuncts:
2011 [39]	23	the prehospital	2. NR	via GVSL	1. GSVL could be a valuable support
2011 [39]		Setting	2. NR 3. NR	2. Conventional	instrument in the prehospital emergency
		Setting	5.100	laryngoscopy	management of difficult airways
Cobas	203	Patients requiring	1. NR	1. Prehospital	Prehospital intubation:
2009 [36]		emergency	$2.42.0^{a}(20)$	intubation (failures)	1. 31% failed PHI; no mortality difference
L - J		prehospital	3.73%	2. No comparator	between properly vs improperly intubated
		intervention		1	2. BVM can adequately manage airways in
					trauma patients who cannot be intubated
Respiratory/B	reathing				
Bozzay	115	Patients treated in	1. 30.8 ^a (11.6)	1. Thoracostomy tube	Thoracostomy:
2018 [44]		the prehospital	2. 24.7 ^a (5.4)	insertion	1. Number of TTs placed significantly \uparrow RH
		Setting	3.99.1%	2. No comparator	development (p=0.0439)
Lesperance	477	Patients treated in	1. 29.6 ^a (14.6)	1. Prehospital needle	Prehospital needle decompression:
2018 [42]		the prehospital	2. 41.5 ^a (17.6)	decompression	1. Injured chest wall significantly thicker at
		Setting	3.77.3%	2. No comparator	2^{nd} ICS MCL and 5^{th} ICS AAL (both $p <$
					0.005)
					2. \uparrow chest wall thickness correlated with
***	1.50		1 51 44		catheter failure to reach pleural space
Weichenthal	169	Patients assessed	1. 71.64 ^a	1. NT	Needle thoracostomy:
2016 [48]		by EMS	2. 38.0 ^a	2. No comparator	1. Safe when performed by EMS paramedics
		I	3.87%		in most settings

					2. Effective in blunt and penetrating trauma patients, most beneficial when unstable
Blenkinsop 2015 [50]	63	Patients treated in the prehospital Setting	1. NR 2. 24.0 ^b (21- 27) 3. 100%	1. NCD 2. No comparator	Needle chest decompression: 1. No significant difference between sites 2. 55mm catheter will decompress 99% of tension PTX without complications; >60mm not recommended
Weichenthal 2015 [47]	64	Patients treated in the prehospital Setting	1. NR 2. 40.0 ^a 3. 84%	1. NT with >60min Transport time 2. NT with <60min Transport time	Needle thoracostomy: 1. No significant difference in survival in prolonged vs short transport times
Ball 2010 [46]	101	Traumatic injuries requiring prehospital intervention	1. NR 2. NR 3. NR	 NT placed by HEMS NT placed by GEMS 	 Needle thoracostomy: 1. Tension PTX decompression using 3.2cm catheter failed in 65% 2. 4.5cm catheter ↓ failure rate
Blaivas 2010 [49]	57	Patients treated on arrival via EMS to ED	1. NR 2. NR 3. NR	 NT followed by US in Emergency Room No comparator 	Needle thoracostomy: 1. 26% of prehospital patients with suspected PTX appeared to not have a PTX originally; patient should be evaluated with bedside US first
Matsumoto 2009 [26]	34	Cardiac arrest patients with blunt trauma	1. NR 2. NR 3. 64.7%	 Prehospital thoracotomy No comparator 	Prehospital thoracotomy: 1. No survivors 2. Early access to an emergency field thoracotomy may improve possibility of survival
Aylwin 2008 [41]	52	Patients requiring either prehospital or ED intervention	1. NR 2. 29.0 ^b (22- 29) 3. 85%	 Prehospital thoracostomy No comparator 	 Prehospital thoracostomy: 1. 61% appropriately indicated for suspected tension PTX 2.14% complication rate; 31% chest tubes poorly placed; 17% required repositioning. 3. Pleural drainage has potential to cause life-threatening injury, especially prehospital
Warner 2008 [51]	28	Patients treated in the prehospital Setting	1. NR 2. NR 3. NR	1. NT 2. No comparator	Needle thoracostomy: 1. EMS NT safe and resulted in four cases of unexpected survival
Davis 2005 [52]	81	Trauma patient requiring intervention by aeromedical crews	1. NR 2. NR 3. NR	1. NT 2. TT	All interventions: 1. ↓ complication rate and a small but significant group of unexpected survivors support use of these by aeromedical staff
Spanjersberg 2005 [45]	149	Patients treated en-route or in ED	1. 23.3 ^a 2. NR 3. 82.55%	 Prehospital TT ED TT 	Tube thoracostomy: 1. Infected hemothoraces were non- significantly related to 9% of prehospital and 12% of ED-performed TTs
Circulation					
Boudreau 2019 [65]	116	Patients treated en-route or in ED	1. NR 2. NR 3. NR	1. TXA en-route (HEMS) 2. TXA in ED	Tranexamic acid: 1. No difference in complications or mortality
Cornelius 2018 [64]	133	Trauma patient with hemorrhage \pm signs of shock and ISS ≥ 20	1. All≥20.0 2. NR 3. NR	1. TXA 2. Non-TXA	Tranexamic acid: 1. Non-TXA: less acutely injured, ↓ LOS and improved outcomes 2. Severely injured TXA survived despite high TRISS
Heschl 2018 [58]	1267	Patients treated in the prehospital setting	1. 36.5 ^a (15.8) 2. 42.6 ^a (20.9) 3. 66.7%	 Transfusion of RCCs (HEMS) No comparator 	RCC transfusion: 1. HEMS RCC transfusion is feasible

Maddry	650	Trauma patients	1. 27.0 ^a (13.3)	1. TV + ARDSNet	ARDSNet compliant ventilation:
2018 [43]		requiring air	2. 27.0 ^a (7.4)	table compliant	1. \downarrow ventilator days, ICU days, and 30-day
		transport	3.98%	2. TV + ARDSNet	mortality
				table non-compliant	
Moore	144	Injured adults	1. NR	1. Plasma	Plasma administration:
2018 [70]		with acute blood	2. NR	2. Usual care	1. Use not associated with \uparrow survival
		loss	3. NR		
Sperry	501	Injured patients at	1. 22.0 ^b (13-	1. Plasma	Plasma administration:
2018 [55]		risk for	30)	2. Standard-care	1. Prehospital administration safe and \downarrow 30-
		hemorrhagic	2. NR		day mortality and \downarrow median PT
		shock during air	3. NR		
		transport			
Vitalis	28	Urgently injured	1. 25.0 ^b (21-	1. Battlefield blood	Battlefield transfusion:
2018 [54]		or need surgical	38)	transfusion	1. \downarrow time to first blood product transfusion
[]		treatment <90min	2. NR	2. No transfusion	for alpha casualties; FLYP is 1st line
		during combat	3.96%	2. Tto transfusion	battlefield blood product
Holcomb	1058	Trauma patients	1. 17.0 ^b (9-29)	1. Prehospital blood	Prehospital blood products:
2017 [53]	1000	transported by	2. 38.0 ^b (25-	products	1. Inconclusive results due to imbalance in
2017 [33]		helicopter	55)	2. Crystalloid (no	SBP, GCS, and ISS between groups; unable
		nencopier	3.71%	blood products)	to compare
Schauer	272	Patients with	$1.20.1^{a}(18)$	1. TXA	Tranexamic acid:
2017 [68]	212	hypotension,	2. NR	1. 1XA 2. No TXA	1. Overall proportions of patients receiving
2017 [08]		amputation, or	2. NR 3. NR	2. NO 1AA	TXA were low despite emphasis in the
		penetrating torso	5. INK		guidelines
					guidennes
Shackelford	502	trauma	1 ND	1. Prehospital	Drob conital transfusion.
	502	US military	1. NR		Prehospital transfusion:
2017 [60]		combat	2. NR	transfusion	1. Use within minutes of injury associated
		casualties	3.98%	2. No prehospital	with ↑ 24hr and 30d survival vs delayed
				transfusion but	transfusion or no transfusion
				matched	
				3. No prehospital	
3 6111	2071		1.10	transfusion	
Miller	3071	Adult trauma air	1. NR	1. Prehospital blood	Prehospital blood transfusion:
2016 [62]		transported from	2. NR	transfusion	1. No effect on 24-hr and overall in-hospital
		the scene to	3. NR	2. No prehospital	mortality
G 11	10/7	trauma center	1.10	blood transfusion	
Savell	1267	US military	1. NR	1. PIV	Intraosseous access:
2016 [69]		personnel	2. NR	2. IO	1. Successfully used in the combat setting
				A DIV. 10	
		transported by	3. NR	3. PIV + IO	2. Accounts for ~12% of vascular access in
		transported by MEDEVAC		3. PIV + IO4. No IV access	
		transported by MEDEVAC teams	3. NR	4. No IV access	2. Accounts for ~12% of vascular access in the MEDEVAC population
Auten	61	transported by MEDEVAC teams Severely battle-	3. NR 1. NR	4. No IV access 1. CTx / FWB	2. Accounts for ~12% of vascular access in the MEDEVAC population FWB:
	61	transported by MEDEVAC teams Severely battle- injured personnel	3. NR 1. NR 2. NR	4. No IV access	 2. Accounts for ~12% of vascular access in the MEDEVAC population FWB: 1. Early use in resource-limited settings ↓
2015 [59]		transported by MEDEVAC teams Severely battle- injured personnel with ISS ≥15	3. NR 1. NR 2. NR 3. 100%	4. No IV access1. CTx / FWB2. CTx	 2. Accounts for ~12% of vascular access in the MEDEVAC population FWB: 1. Early use in resource-limited settings ↓ traumatic coagulopathy
2015 [59] Jansen	61 791	transported by MEDEVAC teams Severely battle- injured personnel	3. NR 1. NR 2. NR 3. 100% 1. 22.0 ^b	4. No IV access1. CTx / FWB2. CTx1. Massive	 2. Accounts for ~12% of vascular access in the MEDEVAC population FWB: Early use in resource-limited settings ↓ traumatic coagulopathy Massive transfusion:
2015 [59]		transported by MEDEVAC teams Severely battle- injured personnel with ISS ≥15 Bleeding trauma	3. NR 1. NR 2. NR 3. 100% 1. 22.0 ^b 2. 22.0 ^b (19-	 4. No IV access 1. CTx / FWB 2. CTx 1. Massive transfusion 	 2. Accounts for ~12% of vascular access in the MEDEVAC population FWB: Early use in resource-limited settings ↓ traumatic coagulopathy Massive transfusion: Massive transfusion ↑ survival vs civilian
2015 [59] Jansen		transported by MEDEVAC teams Severely battle- injured personnel with ISS ≥15 Bleeding	3. NR 1. NR 2. NR 3. 100% 1. 22.0 ^b 2. 22.0 ^b (19- 25)	 4. No IV access 1. CTx / FWB 2. CTx 1. Massive transfusion 2. Non-massive 	 2. Accounts for ~12% of vascular access in the MEDEVAC population FWB: Early use in resource-limited settings ↓ traumatic coagulopathy Massive transfusion:
2015 [59] Jansen 2014 [67]	791	transported by MEDEVAC teams Severely battle- injured personnel with ISS ≥15 Bleeding trauma patients	3. NR 1. NR 2. NR 3. 100% 1. 22.0 ^b 2. 22.0 ^b (19- 25) 3. 99.1%	 4. No IV access 1. CTx / FWB 2. CTx 1. Massive transfusion 2. Non-massive transfusion 	 2. Accounts for ~12% of vascular access in the MEDEVAC population FWB: Early use in resource-limited settings ↓ traumatic coagulopathy Massive transfusion: Massive transfusion ↑ survival vs civilian patients
2015 [59] Jansen 2014 [67] Nadler		transported by MEDEVAC teams Severely battle- injured personnel with ISS ≥15 Bleeding trauma patients Patients	3. NR 1. NR 2. NR 3. 100% 1. 22.0 ^b 2. 22.0 ^b (19- 25) 3. 99.1% 1. 16.0 ^b (9-25)	 4. No IV access 1. CTx / FWB 2. CTx 1. Massive transfusion 2. Non-massive transfusion 1. Military personnel 	 2. Accounts for ~12% of vascular access in the MEDEVAC population FWB: Early use in resource-limited settings ↓ traumatic coagulopathy Massive transfusion: Massive transfusion ↑ survival vs civilian patients Tranexamic acid:
2015 [59] Jansen 2014 [67] Nadler	791	transported by MEDEVAC teams Severely battle- injured personnel with ISS ≥15 Bleeding trauma patients	3. NR 1. NR 2. NR 3. 100% 1. 22.0 ^b 2. 22.0 ^b (19- 25) 3. 99.1% 1. 16.0 ^b (9-25) 2. NR	 4. No IV access 1. CTx / FWB 2. CTx 1. Massive transfusion 2. Non-massive transfusion 1. Military personnel TXA 	 2. Accounts for ~12% of vascular access in the MEDEVAC population FWB: Early use in resource-limited settings ↓ traumatic coagulopathy Massive transfusion: Massive transfusion ↑ survival vs civilian patients
2015 [59] Jansen	791	transported by MEDEVAC teams Severely battle- injured personnel with ISS ≥15 Bleeding trauma patients Patients	3. NR 1. NR 2. NR 3. 100% 1. 22.0 ^b 2. 22.0 ^b (19- 25) 3. 99.1% 1. 16.0 ^b (9-25)	 4. No IV access 1. CTx / FWB 2. CTx 1. Massive transfusion 2. Non-massive transfusion 1. Military personnel 	 2. Accounts for ~12% of vascular access in the MEDEVAC population FWB: Early use in resource-limited settings ↓ traumatic coagulopathy Massive transfusion: Massive transfusion ↑ survival vs civilian patients Tranexamic acid:
2015 [59] Jansen 2014 [67] Nadler	791	transported by MEDEVAC teams Severely battle- injured personnel with ISS ≥15 Bleeding trauma patients Patients treated	3. NR 1. NR 2. NR 3. 100% 1. 22.0 ^b 2. 22.0 ^b (19- 25) 3. 99.1% 1. 16.0 ^b (9-25) 2. NR	 4. No IV access 1. CTx / FWB 2. CTx 1. Massive transfusion 2. Non-massive transfusion 1. Military personnel TXA 	 2. Accounts for ~12% of vascular access in the MEDEVAC population FWB: Early use in resource-limited settings ↓ traumatic coagulopathy Massive transfusion: Massive transfusion ↑ survival vs civilian patients Tranexamic acid: Administering in the field is feasible in
2015 [59] Jansen 2014 [67] Nadler 2014 [66] Perkins	791	transported by MEDEVAC teams Severely battle- injured personnel with ISS ≥15 Bleeding trauma patients Patients treated at scene Patients admitted	3. NR 1. NR 2. NR 3. 100% 1. 22.0 ^b 2. 22.0 ^b (19- 25) 3. 99.1% 1. 16.0 ^b (9-25) 2. NR 3. NR 1. NR	 4. No IV access 1. CTx / FWB 2. CTx 1. Massive transfusion 2. Non-massive transfusion 1. Military personnel TXA 2. Civilian TXA 1. FWB 	 2. Accounts for ~12% of vascular access in the MEDEVAC population FWB: Early use in resource-limited settings ↓ traumatic coagulopathy Massive transfusion: Massive transfusion ↑ survival vs civilian patients Tranexamic acid: Administering in the field is feasible in the civilian and the military setting
2015 [59] Jansen 2014 [67] Nadler 2014 [66]	791	transported by MEDEVAC teams Severely battle- injured personnel with ISS ≥15 Bleeding trauma patients Patients treated at scene Patients admitted to combat support	3. NR 1. NR 2. NR 3. 100% 1. 22.0 ^b 2. 22.0 ^b (19- 25) 3. 99.1% 1. 16.0 ^b (9-25) 2. NR 3. NR 1. NR 2. NR	 4. No IV access 1. CTx / FWB 2. CTx 1. Massive transfusion 2. Non-massive transfusion 1. Military personnel TXA 2. Civilian TXA 	 2. Accounts for ~12% of vascular access in the MEDEVAC population FWB: Early use in resource-limited settings ↓ traumatic coagulopathy Massive transfusion: Massive transfusion ↑ survival vs civilian patients Tranexamic acid: Administering in the field is feasible in the civilian and the military setting In interventions: No difference in survival between FWB
2015 [59] Jansen 2014 [67] Nadler 2014 [66] Perkins 2011 [56]	791 103 369	transported by MEDEVAC teams Severely battle- injured personnel with ISS ≥15 Bleeding trauma patients Patients treated at scene Patients admitted to combat support hospital	3. NR 1. NR 2. NR 3. 100% 1. 22.0 ^b 2. 22.0 ^b (19- 25) 3. 99.1% 1. 16.0 ^b (9-25) 2. NR 3. NR 1. NR 2. NR 3. NR	 4. No IV access 1. CTx / FWB 2. CTx 1. Massive transfusion 2. Non-massive transfusion 1. Military personnel TXA 2. Civilian TXA 1. FWB 2. Apheresis platelets 	 2. Accounts for ~12% of vascular access in the MEDEVAC population FWB: Early use in resource-limited settings ↓ traumatic coagulopathy Massive transfusion: Massive transfusion ↑ survival vs civilian patients Tranexamic acid: Administering in the field is feasible in the civilian and the military setting All interventions: No difference in survival between FWB or aPLT at 24 hours or at 30 days
2015 [59] Jansen 2014 [67] Nadler 2014 [66] Perkins	791	transported by MEDEVAC teams Severely battle- injured personnel with ISS ≥15 Bleeding trauma patients Patients treated at scene Patients admitted to combat support	3. NR 1. NR 2. NR 3. 100% 1. 22.0 ^b 2. 22.0 ^b (19- 25) 3. 99.1% 1. 16.0 ^b (9-25) 2. NR 3. NR 1. NR 2. NR	 4. No IV access 1. CTx / FWB 2. CTx 1. Massive transfusion 2. Non-massive transfusion 1. Military personnel TXA 2. Civilian TXA 1. FWB 	 2. Accounts for ~12% of vascular access in the MEDEVAC population FWB: Early use in resource-limited settings ↓ traumatic coagulopathy Massive transfusion: Massive transfusion ↑ survival vs civilian patients Tranexamic acid: Administering in the field is feasible in the civilian and the military setting In the reventions: No difference in survival between FWB

Wade 2010 [57]	2050	US military trauma patients	1. NR 2. NR	1. rFVIIa 2. No rFVIIa	rFVIIa use: 1. Not associated with an improvement in
2010 [37]		trauma patients	2. NR 3. NR	2. NO IF V IIa	survival or an \uparrow in complications
Hypothermia	Prevention	1			
Lundgren 2011 [16]	48	Patients with outdoor injury transported by EMS	1. NR 2. NR 3. 39.6%	 Passive warming Active warming 	 Warming methods: 1. In mild hypothermia, prehospital passive warming slows rewarming rate and reduces cold discomfort 2. Adding active warming significantly ↑ thermal comfort and ↓ cold induced stress
Cassidy 2001 [71]	20	Hypothermic patients	1. NR 2. NR 3. NR	 Warmed IVF Non-warmed IVF 	 IVF: 1. Prehospital IVF can be warmed in the field and can help ↓ morbidity and mortality from hypothermia
E-FAST					
O'Dochartaigh 2017 [76]	299	Patients requiring air medical transport	1. NR 2. NR 3. NR	 PHUS No comparator 	Prehospital Ultrasound: 1. Supported use in medical and trauma patients with markers of higher acuity during HEMS transport
Yates 2017 [77]	190	Blunt and penetrating trauma patients	1. NR 2. NR 3. NR	 E-FAST by flight crew E-FAST by trauma team 	 E-FAST examination: 1. ↑ ability to assess patients in austere air medical and prehospital environments, help establish an early diagnosis, and ↓ iatrogenic injury potential
Kirkpatrick 2004 [75]	225	Patients in physiologic extremes and suspected of having PTXs	1. 14.0 ^b (5-27) 2. 37.0 ^b 3. 74%	 E-FAST Examination E-FAST and CT scan CT scan vs CXR 	 E-FAST examination: 1. Comparable specificity to CXR, more sensitive for occult PTX detection 2. + E-FAST findings should be addressed clinically or with CT depending on hemodynamic stability; use CT if detection of all PTXs desired
Mixed	•			•	•
Meizoso 2015 [73]	3733	Patients arriving via EMS from injury scene	1. 5.0 ^b (1-14) 2. 39.0 ^a (19) 3. 74%	1. PHI 2. No PHI	Prehospital interventions: 1. ↓ mortality in severely injured trauma patients and do not delay transport to definitive care
Mahshidfar 2013 [74]	60	Patients with possible spinal trauma	1. NR 2. NR 3. NR	 Long Backboard Vacuum Mattress Splint 	All interventions: 1. Long backboard ↑ immobilization, easier to use, and ↓ time to perform
Cancio 2008 [72]	192	Patients air transported to three urban Level I trauma centers	1. NR 2. NR 3. 71.7%	 LSIs Usual care 	Lifesaving interventions: 1. HRC may help identify the severely injured

Legend: * - mean or median, a – mean, b – median, AAL – anterior axillary line, aPLT – apheresis platelet, BVM – bag valve mask, CTx – component therapy, CTY – cricothyrotomy, CXR – chest x-ray, E-FAST – Extended Focused Assessment with Sonography in Trauma, ETI – endotracheal intubation, FLYP – French lyophilized plasma, FWB – fresh whole blood, GCS – Glasgow coma scale, GEMS – ground emergency medical services, GSVL – Glidescope video laryngoscope, GSW – gunshot wound, HEMS – helicopter emergency medical service, HRC – heart rate complexity, ICS – intercostal space, IDF – Israeli Defense Force, IED – improvised explosive device, IO – intraosseous, IVF – intravenous fluid, LL – lower limb, LMA – laryngeal mask airway, LSI – life saving intervention, MCL – midclavicular line, NCD – needle chest decompression, NISS – new injury severity score, NPWT – negative pressure wound therapy, NR – not reported, NT – needle thoracostomy, PHI – prehospital intervention, PHUS – prehospital ultrasound, PIV – peripheral intravenous line, POCUS – point of care ultrasound, PT – prothrombin time, PTX – pneumothorax, QCCG – QuikClot® Combat Gauze®, RCC – red cell concentrate, RH – retained hemothorax, SBP – systolic blood pressure, SGA – supraglottic airway, TRISS – trauma revised injury severity score, TT – tube thoracostomy, TV – tidal volume, TVS – temporary vascular shunt, TXA – tranexamic acid.